Skip to main content
. Author manuscript; available in PMC: 2015 Oct 21.
Published in final edited form as: Vaccine. 2014 Sep 13;32(46):6138–6145. doi: 10.1016/j.vaccine.2014.08.070

Table I.

Adverse Events

HBsAg + ABX196
HBsAg
n = 7
Heberbiovac
n = 8
HBsAg + ABX196 0.2 µg
n = 6
HBsAg + ABX196 0.4 µg
n = 11
HBsAg + ABX196 2 µg
n = 12
TEAE Number 24 18 26 115 110
% Subjects 85.7% 87.5% 66.7% 100.0% 100.0%
Moderate and Severe TEAE Number 8 1 10 36 37
% Subjects 42.9% 12.5% 33.3% 90.9% 91.7%

TEAE: Treatment Emergent Adverse Event

HHS Vulnerability Disclosure